SE529185C2 - Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt - Google Patents

Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt

Info

Publication number
SE529185C2
SE529185C2 SE0502214A SE0502214A SE529185C2 SE 529185 C2 SE529185 C2 SE 529185C2 SE 0502214 A SE0502214 A SE 0502214A SE 0502214 A SE0502214 A SE 0502214A SE 529185 C2 SE529185 C2 SE 529185C2
Authority
SE
Sweden
Prior art keywords
product
obesity
food
mice
probiotic
Prior art date
Application number
SE0502214A
Other languages
English (en)
Swedish (sv)
Other versions
SE0502214L (sv
Inventor
Kajsa Ohlson
Margit Mahlapuu
Ulla Svensson
Original Assignee
Arla Foods Amba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE529185(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arla Foods Amba filed Critical Arla Foods Amba
Priority to SE0502214A priority Critical patent/SE529185C2/sv
Priority to BRPI0616993-7A priority patent/BRPI0616993A2/pt
Priority to EP06799717A priority patent/EP1945235B1/en
Priority to JP2008534487A priority patent/JP2009511469A/ja
Priority to SI200631495T priority patent/SI1945235T1/sl
Priority to AU2006299956A priority patent/AU2006299956B2/en
Priority to PT67997171T priority patent/PT1945235E/pt
Priority to ES06799717T priority patent/ES2396865T3/es
Priority to PCT/SE2006/001117 priority patent/WO2007043933A1/en
Priority to ES11191774.6T priority patent/ES2567404T3/es
Priority to DK06799717.1T priority patent/DK1945235T3/da
Priority to CN2006800368040A priority patent/CN101287478B/zh
Priority to US12/089,433 priority patent/US20080267933A1/en
Priority to DK11191774.6T priority patent/DK2431044T3/en
Priority to CA002624890A priority patent/CA2624890A1/en
Priority to EA200800913A priority patent/EA015461B1/ru
Priority to EP11191774.6A priority patent/EP2431044B1/en
Priority to PL06799717T priority patent/PL1945235T3/pl
Publication of SE0502214L publication Critical patent/SE0502214L/xx
Publication of SE529185C2 publication Critical patent/SE529185C2/sv
Priority to CY20121101262T priority patent/CY1113704T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0502214A 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt SE529185C2 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
PL06799717T PL1945235T3 (pl) 2005-10-07 2006-10-02 Probiotyki wpływające na metabolizm tłuszczu i otyłość
PCT/SE2006/001117 WO2007043933A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
DK06799717.1T DK1945235T3 (da) 2005-10-07 2006-10-02 Probiotika til at påvirke fedtmetabolisme og fedme
JP2008534487A JP2009511469A (ja) 2005-10-07 2006-10-02 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス
SI200631495T SI1945235T1 (sl) 2005-10-07 2006-10-02 Probiotiki, ki vplivajo na presnovo maščob in debelost
AU2006299956A AU2006299956B2 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
PT67997171T PT1945235E (pt) 2005-10-07 2006-10-02 Probióticos para influenciar o metabolismo da gordura e a obesidade
ES06799717T ES2396865T3 (es) 2005-10-07 2006-10-02 Probióticos para influenciar el metabolismo de las grasas y la obesidad
BRPI0616993-7A BRPI0616993A2 (pt) 2005-10-07 2006-10-02 bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas
ES11191774.6T ES2567404T3 (es) 2005-10-07 2006-10-02 Probióticos para influir en el metabolismo de las grasas y la obesidad
EP06799717A EP1945235B1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
CN2006800368040A CN101287478B (zh) 2005-10-07 2006-10-02 影响脂肪代谢和肥胖的益生菌
US12/089,433 US20080267933A1 (en) 2005-10-07 2006-10-02 Probiotics to Influence Fat Metabolism and Obesity
DK11191774.6T DK2431044T3 (en) 2005-10-07 2006-10-02 Probiotics to affect fat metabolism and obesity
CA002624890A CA2624890A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
EA200800913A EA015461B1 (ru) 2005-10-07 2006-10-02 Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах
EP11191774.6A EP2431044B1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
CY20121101262T CY1113704T1 (el) 2005-10-07 2012-12-27 Προβιοτικα που επηρεαζουν τον μεταβολισμο του λιπους και την παχυσαρκια

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt

Publications (2)

Publication Number Publication Date
SE0502214L SE0502214L (sv) 2007-04-08
SE529185C2 true SE529185C2 (sv) 2007-05-22

Family

ID=37943064

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt

Country Status (16)

Country Link
US (1) US20080267933A1 (https=)
EP (2) EP1945235B1 (https=)
JP (1) JP2009511469A (https=)
CN (1) CN101287478B (https=)
AU (1) AU2006299956B2 (https=)
BR (1) BRPI0616993A2 (https=)
CA (1) CA2624890A1 (https=)
CY (1) CY1113704T1 (https=)
DK (2) DK2431044T3 (https=)
EA (1) EA015461B1 (https=)
ES (2) ES2396865T3 (https=)
PL (1) PL1945235T3 (https=)
PT (1) PT1945235E (https=)
SE (1) SE529185C2 (https=)
SI (1) SI1945235T1 (https=)
WO (1) WO2007043933A1 (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085970A2 (en) * 2006-01-27 2007-08-02 Danisco A/S Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
US9084434B2 (en) * 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP2011506A1 (en) 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
BRPI0721863A2 (pt) * 2007-07-25 2014-02-18 Danisco Composição para induzir ou melhorar a sensação de satisfação e/ou saciedade, método para identificar e/ou isolar bactérias que são capazes de induzir ou melhorar satisfação e/ou saciedade, cepa bacteriana, uso de uma cepa bacteriana, e, método para preparar um alimento, suplemento alimentício ou composição alimetícia que melhora satisfação e/ou saciedade.
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
JP5225652B2 (ja) * 2007-10-29 2013-07-03 雪印メグミルク株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
AU2008333718B2 (en) 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
FR2930264B1 (fr) * 2008-04-18 2013-02-22 Gervais Danone Sa Nouvelle souche de lactobacillus paracasei subsp. paracasei dotee de proprietes antimicrobiennes et immunomodulatrices.
EP2123168B1 (en) * 2008-05-16 2011-12-21 Nestec S.A. Lactobacillus paracasei and weight control
WO2009142713A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal
AU2009282482B2 (en) * 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
CA2753083C (en) * 2009-03-06 2021-04-20 Federation Des Producteurs Acericoles Du Quebec Symbiotic maple product compositions and methods
EP2407170B1 (en) * 2009-03-10 2015-03-25 Jinis Biopharmaceuticals Co. Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
DK2411027T3 (en) * 2009-03-25 2015-01-19 Chr Hansen As USING a probiotic ADJUSTING body weight
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
EP3181134B1 (en) 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
JP5436991B2 (ja) * 2009-09-10 2014-03-05 国立大学法人北海道大学 ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
CN107574131A (zh) 2009-11-11 2018-01-12 营养健康有限公司 益生菌双歧杆菌菌株
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
KR101873193B1 (ko) * 2010-06-08 2018-07-02 아사히 그룹 홀딩스 가부시키가이샤 지질 대사 개선제
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
US9636367B2 (en) * 2011-10-18 2017-05-02 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
EP2925333A1 (en) 2012-11-12 2015-10-07 Compagnie Gervais Danone Lactobacillus rhamnosus strain for reducing body fat accumulation
MY183171A (en) * 2013-04-17 2021-02-18 Suntory Holdings Ltd Composition containing bacterium belonging to genus lactobacillus
ES2526986B1 (es) 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
KR101545551B1 (ko) 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
US20160354418A1 (en) * 2014-02-14 2016-12-08 Vesale Pharma Sa Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
MX2017001734A (es) * 2014-08-08 2017-04-27 Nestec Sa Mioinositol y probioticos y usos.
CN104186655B (zh) * 2014-08-27 2016-06-29 内蒙古伊利实业集团股份有限公司 具有降血脂及抗氧化功能的低脂发酵乳及其制备方法
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
CN109312297B (zh) * 2015-12-11 2022-09-23 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
KR20220001516A (ko) * 2016-04-14 2022-01-05 듀폰 뉴트리션 바이오사이언시즈 에이피에스 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균
CN109089421A (zh) 2017-02-10 2018-12-25 完美（中国）有限公司 新型双歧杆菌益生菌菌株
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
TWI640313B (zh) * 2017-08-18 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制肥胖之用途
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
FR3095761B1 (fr) 2019-05-06 2023-11-10 Lab Attitude Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
AU2020412749A1 (en) 2019-12-27 2022-06-16 Biopolis, S.L. Uses of lipoteichoic acid from Bifidobacteria
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
FR3125945B1 (fr) 2021-08-03 2024-07-12 Setalg Composition pour protéger un microorganisme dans un environnement acide.
KR102445708B1 (ko) 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물
CN118716406A (zh) * 2024-04-30 2024-10-01 卡士乳业(深圳)有限公司 含活性乳双歧杆菌的发酵乳在调节亚健康人群状态中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
SE510813C2 (sv) * 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
US6641808B1 (en) 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP2001097870A (ja) * 1999-09-30 2001-04-10 Snow Brand Milk Prod Co Ltd 乳酸菌を利用した胆汁酸の吸着方法
JP2001292728A (ja) 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6963306B2 (en) * 2001-02-02 2005-11-08 Rosum Corp. Position location and data transmission using pseudo digital television transmitters
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US6565847B1 (en) 2002-07-03 2003-05-20 Vitacost.Com, Inc. Thermogenic weight management composition
US20040014403A1 (en) * 2002-07-16 2004-01-22 Oberkampf Brandon L. CMP point of use filtration
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
US20070098705A1 (en) * 2003-05-22 2007-05-03 Symbiotics Ab Probiotic composition comprising at least two lactic acid bacterial strains which are able to clonise the gatrointestonal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and fiber fermenting property
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
AU2008333718B2 (en) * 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage

Also Published As

Publication number Publication date
EA200800913A1 (ru) 2008-10-30
CA2624890A1 (en) 2007-04-19
DK2431044T3 (en) 2016-04-11
CY1113704T1 (el) 2016-06-22
EP1945235A1 (en) 2008-07-23
CN101287478A (zh) 2008-10-15
SI1945235T1 (sl) 2013-02-28
ES2567404T3 (es) 2016-04-22
WO2007043933A1 (en) 2007-04-19
CN101287478B (zh) 2012-10-03
JP2009511469A (ja) 2009-03-19
EA015461B1 (ru) 2011-08-30
US20080267933A1 (en) 2008-10-30
SE0502214L (sv) 2007-04-08
AU2006299956B2 (en) 2012-03-15
AU2006299956A1 (en) 2007-04-19
DK1945235T3 (da) 2013-01-14
ES2396865T3 (es) 2013-02-28
EP2431044A1 (en) 2012-03-21
EP2431044B1 (en) 2016-01-13
BRPI0616993A2 (pt) 2011-07-05
EP1945235B1 (en) 2012-09-26
EP1945235A4 (en) 2009-11-11
PT1945235E (pt) 2013-01-14
PL1945235T3 (pl) 2013-03-29

Similar Documents

Publication Publication Date Title
SE529185C2 (sv) Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
EP2178543B1 (en) Lactobacillus rhamnosus and weight control
AU2019261707A1 (en) Prebiotics for reducing the risk of obesity later in life
AU2011351419A1 (en) A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
CN106036911A (zh) 一种调节血糖水平的益生菌膳食组合物及功能食品
SG191417A1 (en) Fiber and probiotics for reducing intestinal symptoms related to stress
WO2023176952A1 (ja) 腸管内での細菌の増殖制御用組成物及びその利用
EP4358983A1 (en) Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
EP1738761A1 (en) Preventive and/or remedy for inflammatory bowel diseases
Sanders Use of probiotics and yogurts in maintenance of health
CN120390793A (zh) 黏膜乳杆菌和需要glp-1增加的疾病
Moszak et al. Does gut microbiota affect the success of weight loss? Evidence and speculation
CN118900639A (zh) 柯林斯菌属细菌的增殖控制用组合物及其应用
Reehana et al. Synbiotics in Nutrition
CN115404187B (zh) 一种体重管理及减压的益生菌组合物
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
US20190307802A1 (en) Probiotic compositions including immune modulators
Prokopidis Probiotics, prebiotics, and synbiotics to counteract sarcopenia: where are we now and what challenges need to be faced?
MX2008004578A (en) Probiotics to influence fat metabolism and obesity
Sharma et al. 13 Probiotics and Its Efficacy Assessment in Diabetic Intervention
HK1239568A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1239568A1 (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
GÜRÇAY PREBIOTICS AND PROBIOTICS
HK1239564A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases

Legal Events

Date Code Title Description
NUG Patent has lapsed